Research programme: antibacterials - MerLion/Vernalis

Drug Profile

Research programme: antibacterials - MerLion/Vernalis

Alternative Names: Antibacterials research programme - MerLion/Vernalis

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MerLion Pharmaceuticals; Vernalis
  • Class
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 10 Oct 2018 Vernalis was acquired by Ligand Pharmaceuticals
  • 14 Jan 2005 Discontinued - Preclinical for Bacterial infections in Singapore (unspecified route)
  • 14 Jan 2005 Discontinued - Preclinical for Bacterial infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top